Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-1997 | 12-1996 | 12-1995 | 12-1994 | 12-1993 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -30,710 | -23,766 | -72,520 | -29,586 | -29,229 |
| Depreciation Amortization | 1,510 | 1,515 | 1,546 | 1,009 | 1,297 |
| Other Working Capital | -3,320 | -3,229 | -4,208 | -422 | 8,962 |
| Other Operating Activity | 690 | 521 | 49,458 | 1,354 | 3,591 |
| Operating Cash Flow | $-31,830 | $-24,959 | $-25,724 | $-27,645 | $-15,379 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -650 | -886 | -595 | -2,835 | -1,555 |
| Net Acquisitions | 0 | 0 | 6,992 | 0 | N/A |
| Other Investing Activity | 3,900 | -12,840 | -1,550 | 19,690 | 13,171 |
| Investing Cash Flow | $3,250 | $-13,726 | $4,847 | $16,855 | $11,616 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 15,680 | 31,430 | 40,728 | 14,416 | 4,960 |
| Financing Cash Flow | $15,680 | $31,430 | $40,728 | $14,416 | $4,960 |
| Beginning Cash Position | 20,290 | 27,551 | 7,700 | 4,074 | 2,877 |
| End Cash Position | 7,400 | 20,296 | 27,551 | 7,700 | 4,074 |
| Net Cash Flow | $-12,890 | $-7,255 | $19,851 | $3,626 | $1,197 |
| Free Cash Flow | |||||
| Operating Cash Flow | -31,830 | -24,959 | -25,724 | -27,645 | -15,379 |
| Free Cash Flow | -31,830 | -24,959 | -25,724 | -27,645 | -15,379 |